Christensen Jakob Wedel Sells 1,033 Shares of Illumina (NASDAQ:ILMN) Stock

Illumina, Inc. (NASDAQ:ILMN) SVP Christensen Jakob Wedel sold 1,033 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the transaction, the senior vice president directly owned 14,023 shares in the company, valued at $2,685,684.96. The trade was a 6.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Illumina Stock Performance

Illumina stock traded up $8.24 during mid-day trading on Thursday, hitting $213.24. 3,249,831 shares of the company’s stock traded hands, compared to its average volume of 1,908,677. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The firm has a 50 day simple moving average of $185.90 and a two-hundred day simple moving average of $151.49. Illumina, Inc. has a fifty-two week low of $88.00 and a fifty-two week high of $220.32. The stock has a market cap of $32.20 billion, a price-to-earnings ratio of 39.78, a P/E/G ratio of 2.65 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating the consensus estimate of $1.23 by $0.08. The firm had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company’s quarterly revenue was up 9.4% on a year-over-year basis. During the same period in the previous year, the company earned $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, research analysts expect that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have weighed in on ILMN. Royal Bank Of Canada increased their price target on shares of Illumina from $170.00 to $230.00 and gave the company an “outperform” rating in a report on Friday, July 31st. Stifel Nicolaus upped their target price on Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Deutsche Bank Aktiengesellschaft lowered Illumina to a “hold” rating in a research note on Wednesday, August 5th. Evercore reissued an “outperform” rating on shares of Illumina in a report on Monday, July 6th. Finally, Weiss Ratings upgraded Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, June 3rd. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $188.40.

Institutional Trading of Illumina

Hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. bought a new stake in Illumina in the 2nd quarter valued at about $3,374,423,000. Primecap Management Co. CA bought a new position in shares of Illumina during the second quarter worth approximately $617,981,000. Jupiter Topco LLC bought a new position in shares of Illumina during the second quarter worth approximately $358,652,000. WCM Investment Management LLC raised its position in shares of Illumina by 45.5% in the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock valued at $715,579,000 after buying an additional 1,851,848 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Illumina in the second quarter valued at approximately $293,846,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.